Resultados de Búsqueda
Current evidence on the safety of therapeutic hypothermia for acute ischaemic stroke shows that there are serious complications. Evidence on efficacy does not show any meaningful improvement in ...
NICE
National Institute for Health and Clinical Excellence (NICE)
It is not recommended to use the therapeutic hypothermia procedure for acute ischaemic stroke as evidence on efficacy does not show any meaningful improvement in outcomes
ver más ... 2019It is recommended to suspect familial hypercholesterolaemia (FH) as a possible diagnosis in adults with a total cholesterol level greater than 7,5 mmol/l or a personal or family history of premature ...
NICE
National Institute for Health and Clinical Excellence (NICE)
For further information please visit the website.
ver más ... 2019Olaparib is recommended for use within the Cancer Drugs Fund as an option for the maintenance treatment of BRCA mutation‑positive, advanced (FIGO stages 3 and 4), high-grade epithelial ovarian, ...
NICE
National Institute for Health and Clinical Excellence (NICE)
This recommendation is not intended to affect treatment with olaparib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. There are currently no maintenance treatments for BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after a ...
ver más ... 2019Rivaroxaban plus aspirin is recommended within its marketing authorisation, as an option for preventing atherothrombotic events in adults with coronary artery disease or symptomatic peripheral artery ...
NICE
National Institute for Health and Clinical Excellence (NICE)
For people with coronary artery disease, high risk of ischaemic events is defined as: - aged 65 or over, or - atherosclerosis in at least 2 vascular territories (such as coronary, cerebrovascular, or peripheral arteries), or - 2 or more of the following risk factors: current smoking, diabetes, kidney dysfunction with an estimated glomerular filtration rate (eGFR) of less than 60 ml/min (note that rivaroxaban is contraindicated if the eGFR is less than 15 ml/min), heart failure, previous ...
ver más ... 2019Rucaparib is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment of relapsed platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal ...
NICE
National Institute for Health and Clinical Excellence (NICE)
This recommendation is not intended to affect treatment with rucaparib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. The clinical evidence shows that rucaparib extends the time until cancer progresses compared with routine care. How much longer ...
ver más ... 2019